Malvern, PA – According to filings with the U.S. Securities and Exchange Commission, VenatoRx Pharmaceuticals is raising $59,999,999.00 in new funding. Sources indicate as part of senior management President, Christopher Burns played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About VenatoRx Pharmaceuticals

Venatorx Pharmaceuticals is a private company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The company name, Venatorx (ven-a-TOREX), derives from the Latin word venator, meaning hunter and rx, the medical symbol for drugs. The pursuit, or hunt, for new drugs is the core mission of our company. Founded in 2010, Venatorx has built a world-class in-house research and development organization that has filed over 120 patents. Venatorxs two lead antibacterial clinical-stage programs are intravenous (cefepime-taniborbactam) and oral (ceftibuten/VNRX-7145) broad-spectrum beta-lactam / beta-lactamase inhibitor combinations that are in Phase 3 and Phase 1, respectively. In addition, the first Venatorx antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor, is in Phase 1 clinical development. The Company also has discovery-stage programs targeting a novel class of non-beta-lactam antibiotics called Penicillin Binding Protein (PBP) inhibitors that have the potential to circumvent 70+ years of resistance and usher in a new wave of antibacterial therapeutics.

To learn more about VenatoRx Pharmaceuticals, visit http://www.venatorx.com/

Contact:
Christopher Burns, President
610-644-8935
burns@venatorx.com
https://www.linkedin.com/in/christopher-burns-67404726/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved